Biomerica GAAP EPS of -$0.37, revenue of $1.3M (NASDAQ:BMRA)
Biomerica reported Q1 GAAP EPS of -$0.37 and revenue of $1.3M, down 7.1% year-over-year. The company had $2.7M in cash as of August 31, 2026, up from $1.3M in May 2026, according to its press release.
How this was made
The 30-second read
Why it matters
The disclosed GAAP loss and revenue contraction are likely to affect near-term valuation and raise questions about burn rate and funding needs, especially for a small-cap issuer.
Market read
This is a direct earnings datapoint for BMRA, providing fresh quarterly financials and liquidity context.
What to watch
The brief lacks guidance, segment performance, and any pipeline or commercialization updates, so the market reaction may overemphasize the headline EPS/revenue without context.
Background
The piece summarizes Biomerica’s Q1 GAAP results and a cash balance snapshot.
Ticker impact
Biomerica reported Q1 GAAP EPS of -$0.37 and revenue of $1.3M, plus cash of about $2.7M as of Aug. 31, 2026.
Likely downward pressure as investors weigh ongoing losses and shrinking revenue against the company’s near-term liquidity.
The article provides the company’s own quarterly GAAP EPS and revenue figures and a cash balance update, which typically drive immediate earnings sentiment for small-cap biotech/diagnostics names.
Market effects
Reinforces risk-off sentiment for small-cap healthcare diagnostics/biotech issuers with low revenue scale and cash constraints.
Limited broader market impact expected given micro-scale revenue and single-company focus.
Primarily US small-cap healthcare sentiment, no clear global spillover from the disclosed figures.
Counterpoint
Investors may focus on the cash balance increase versus May 31, 2026 as evidence of improved financing or working-capital management.
Key entities
- companyBiomerica, Inc.
Reported Q1 GAAP EPS of -$0.37 and revenue of $1.3M, with cash and cash equivalents of about $2.7M as of Aug. 31, 2026.
